Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 72, Issue 12, Pages 1897-1904Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2013-203485
Keywords
Rheumatoid Arthritis; Treatment; DMARDs (biologic)
Categories
Funding
- F. Hoffmann-La Roche Ltd.
- Roche
- National Institute for Health Research [NF-SI-0508-10299] Funding Source: researchfish
- Versus Arthritis
- Cancer Research UK [18475] Funding Source: researchfish
Ask authors/readers for more resources
Clinical evidence demonstrates coadministration of tumour necrosis factor inhibitor (TNFi) agents and methotrexate (MTX) is more efficacious than administration of TNFi agents alone in patients with rheumatoid arthritis, leading to the perception that coadministration of MTX with all biologic agents or oral disease-modifying antirheumatic drugs is necessary for maximum efficacy. Real-life registry data reveal approximately one-third of patients taking biologic agents use them as monotherapy. Additionally, an analysis of healthcare claims data showed that when MTX was prescribed in conjunction with a biologic agent, as many as 58% of patients did not collect the MTX prescription. Given this discrepancy between perception and real life, we conducted a review of the peer-reviewed literature and rheumatology medical congress abstracts to determine whether data support biologic monotherapy as a treatment option for patients with rheumatoid arthritis. Our analysis suggests only for tocilizumab is there evidence that the efficacy of biologic monotherapy is comparable with combination therapy with MTX.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available